Oxoisoindoline Helios Inhibitors for Local Treg Reprogramming
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current cancer and viral infection treatments are hindered by the suppressive activity of Helios-expressing regulatory T cells (Tregs), which impede effective immune responses and promote tumor growth or viral persistence.
Innovation Solution
Substituted oxoisoindoline compounds that inhibit Helios protein by interacting with the Cullin4-Cereblon E3 ubiquitin ligase complex, reducing Helios levels and activity to control Treg differentiation and stability.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If Helios-expressing regulatory T cells are present to maintain immune homeostasis, then autoimmune responses are prevented, but antitumor immune responses are suppressed
Solution Approach 1:
The compound selectively reduces Helios protein levels in intratumoral Tregs while preserving systemic Treg function. This local action allows antitumor immunity to be enhanced at the tumor site without compromising overall immune homeostasis and self-tolerance throughout the body.
Solution Approach 2:
The substituted oxoisoindoline compound acts as an intermediary that targets the Cullin4-Cereblon E3 ubiquitin ligase complex to specifically degrade Helios protein in Tregs within the tumor microenvironment, thereby mediating the conversion of suppressive Tregs to effector T cells locally without systemic immune disruption.
2Object-affected harmful factors
If Treg depletion is performed to enhance antitumor immunity, then tumor growth is inhibited, but autoimmune side effects increase
Solution Approach 1:
The compound exhibits spatial selectivity by acting primarily on Tregs within the tumor microenvironment rather than systemically throughout the body. This localized action converts intratumoral Tregs to effector T cells, inhibiting tumor growth while preserving systemic Treg-mediated immune homeostasis and preventing autoimmune side effects.
Solution Approach 2:
The compound converts the harmful suppressive function of Tregs into a beneficial effector function by inducing phenotype conversion. Intratumoral Tregs are transformed into Teff cells that can attack tumor cells, thereby turning the immune suppression problem into an antitumor immune advantage without depleting Tregs systemically.
3Object-affected harmful factors
If Helios protein levels are reduced to convert Tregs to Teff cells, then antitumor immune response is enhanced, but Treg stability is compromised
Solution Approach 1:
The compound creates a localized effect within the tumor microenvironment where Helios protein levels are reduced in Tregs, inducing phenotype conversion to Teff cells at the tumor site. Systemic Tregs maintain normal Helios levels and phenotype stability, preserving overall Treg population integrity while enhancing antitumor immunity locally.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
These compounds enhance antitumor immune responses and improve treatment efficacy against cancer and viral infections by stabilizing Treg phenotype and enhancing Teff activity, while minimizing autoimmune side effects.
Implementation Method 1
Substituted oxoisoindoline compounds that inhibit Helios protein by interacting with the Cullin4-Cereblon E3 ubiquitin ligase complex
Data Source
AI summary
Disclosed are compounds of Formula (I) or a salt thereof, wherein Ring A is a carbon-linked ring; and Ring A, R1, and n are defined herein. Also disclosed are methods of using such compounds to inhibit Helios protein, and pharmaceutical compositions comprising such compounds. These compounds are useful in the treatment of viral infections and proliferative disorders, such as cancer.